IVF under COVID-19: treatment outcomes of fresh ART cycles.


Journal

Human reproduction (Oxford, England)
ISSN: 1460-2350
Titre abrégé: Hum Reprod
Pays: England
ID NLM: 8701199

Informations de publication

Date de publication:
03 05 2022
Historique:
received: 12 12 2021
revised: 16 02 2022
pubmed: 26 2 2022
medline: 10 5 2022
entrez: 25 2 2022
Statut: ppublish

Résumé

Does prior severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in women undergoing fertility treatments affect the outcomes of fresh ART cycles? SARS-CoV-2 infection does not affect fresh ART treatment outcomes, except for a possible long-term negative effect on oocyte yield (>180 days postinfection). A single previous study suggested no evidence that a history of asymptomatic or mild SARS-CoV-2 infection in females caused impairment of fresh ART treatment outcomes. Retrospective cohort study, including all SARS-CoV-2 infected women who underwent fresh ART cycles within a year from infection (the first cycle postinfection), between October 2020 and June 2021, matched to non-diagnosed controls. Patients from two large IVF units in Israel who were infected with SARS-CoV-2 and later underwent fresh ART cycles were matched by age to non-diagnosed, non-vaccinated controls. Demographics, cycle characteristics and cycle outcomes, including oocyte yield, maturation rate, fertilization rate, number of frozen embryos per cycle and clinical pregnancy rates, were compared between groups. One hundred and twenty-one infected patients and 121 controls who underwent fresh ART cycles were included. Oocyte yield (12.50 versus 11.29; P = 0.169) and mature oocyte rate (78% versus 82%; P = 0.144) in all fresh cycles were similar between groups, as were fertilization rates, number of frozen embryos per cycle and clinical pregnancy rates (43% versus 40%; P = 0.737) in fresh cycles with an embryo transfer. In a logistic regression model, SARS-CoV-2 infection more than 180 days prior to retrieval had a negative effect on oocyte yield (P = 0.018, Slope = -4.08, 95% CI -7.41 to -0.75), although the sample size was small. A retrospective study with data that was not uniformly generated under a study protocol, no antibody testing for the control group. The study findings suggest that SARS-CoV-2 infection does not affect treatment outcomes, including oocyte yield, fertilization and maturation rate, number of good quality embryos and clinical pregnancy rates, in fresh ART cycles, except for a possible long-term negative effect on oocyte yield when retrieval occurs >180 days post-SARS-CoV-2 infection. Further studies are warranted to support these findings. None. 0010-21-HMC, 0094-21-ASF.

Identifiants

pubmed: 35212741
pii: 6536969
doi: 10.1093/humrep/deac043
pmc: PMC8903458
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

947-953

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Michal Youngster (M)

IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, Zerifin, Israel.
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Sarit Avraham (S)

IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, Zerifin, Israel.
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Odelia Yaakov (O)

IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, Zerifin, Israel.

Moran Landau Rabbi (M)

IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, Zerifin, Israel.

Itai Gat (I)

IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, Zerifin, Israel.
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Gil Yerushalmi (G)

IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, Zerifin, Israel.
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Rachael Sverdlove (R)

Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Micha Baum (M)

Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
IVF Unit, Herzliya Medical Centre, Herzliya, Israel.
IVF Unit, Department of Obstetrics and Gynecology, Sheba Medical Centre, Ramat-Gan, Israel.

Ettie Maman (E)

Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
IVF Unit, Herzliya Medical Centre, Herzliya, Israel.
IVF Unit, Department of Obstetrics and Gynecology, Sheba Medical Centre, Ramat-Gan, Israel.

Ariel Hourvitz (A)

IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, Zerifin, Israel.
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Alon Kedem (A)

IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, Zerifin, Israel.
Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
IVF Unit, Herzliya Medical Centre, Herzliya, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH